Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma;...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E.
Target Price
The average target price of ELIC.ST is 8.2 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell